p-AXL与c-MYC和/或BCL-2共表达在弥漫大B细胞性淋巴瘤中的临床意义

缪娜波; 黎绮铭; 李淑华; 聂钊铭; 张芬芬; 彭挺生

您当前的位置：

首页 >

文章列表页 >

p-AXL与c-MYC和/或BCL-2共表达在弥漫大B细胞性淋巴瘤中的临床意义

临床研究 | 更新时间：2023-11-01

- p-AXL与c-MYC和/或BCL-2共表达在弥漫大B细胞性淋巴瘤中的临床意义
- Clinical Significance of Expression of p-AXL and Co-expression with c-MYC and/or BCL-2 in DLBCL
- 中山大学学报（医学科学版） 2020年41卷第4期页码：572-581
- 作者机构：
  
  中山大学附属第一医院病理科，广东广州 510080
- 作者简介：
  
  缪娜波，硕士研究生，研究方向：淋巴瘤病理，E-mail: 994212891@qq.com
- 基金信息：
  
  国家自然科学基金(81872175);广东省科技创新战略专项资金(2018A030313361)
- DOI：
  中图分类号： R733.4
- 收稿：2020-02-29，
  
  纸质出版：2020-07-15
- 稿件说明：
移动端阅览
缪娜波,黎绮铭,李淑华等.p-AXL与c-MYC和/或BCL-2共表达在弥漫大B细胞性淋巴瘤中的临床意义[J].中山大学学报（医学科学版）,2020,41(04):572-581.

MIAO Na-bo,LI Qi-ming,LI Shu-hua,et al.Clinical Significance of Expression of p-AXL and Co-expression with c-MYC and/or BCL-2 in DLBCL[J].Journal of Sun Yat-sen University(Medical Sciences),2020,41(04):572-581.
缪娜波,黎绮铭,李淑华等.p-AXL与c-MYC和/或BCL-2共表达在弥漫大B细胞性淋巴瘤中的临床意义[J].中山大学学报（医学科学版）,2020,41(04):572-581. DOI：

MIAO Na-bo,LI Qi-ming,LI Shu-hua,et al.Clinical Significance of Expression of p-AXL and Co-expression with c-MYC and/or BCL-2 in DLBCL[J].Journal of Sun Yat-sen University(Medical Sciences),2020,41(04):572-581. DOI：

摘要

目的

探索磷酸化酪氨酸激酶p-AXL在弥漫大B细胞性淋巴瘤（DLBCL）中的表达情况及其临床病理意义，并进一步探讨p-AXL与c-MYC和/或BCL-2共表达的临床病理意义，及其与

MYC

断裂基因的临床病理联系。

方法

收集2012-2017年在中山大学附属第一医院确诊为DLBCL的病例118例，将入组的石蜡组织制作成组织芯片。免疫组化法检测DLBCL组织中p-AXL、c-MYC和BCL-2蛋白的表达；荧光原位杂交法（FISH）检测DLBCL组织中

MYC

断裂基因的表达情况。

结果

p-AXL蛋白在DLBCL肿瘤细胞的胞膜和/或胞质中表达；p-AXL表达与DLBCL化疗缓解呈显著性相关（

＜0.01），阳性患者化疗缓解率低于阴性患者；p-AXL表达与Hans分型显著性相关（

＜0.01），p-AXL多见于Non-GCB型；p-AXL与c-MYC、BCL-2及c-MYC/BCL-2蛋白表达均显著性相关（

＜0.01）。p-AXL/c-MYC、p-AXL/BCL-2、p-AXL/c-MYC/BCL-2蛋白共表达均与Hans分型显著性相关（

＜0.01），多见于Non-GCB型。p-AXL与患者无进展生存期(PFS)显著性相关，阳性者PFS低于阴性患者（

＜0.05）；p-AXL阳性者总生存期（OS）亦低于p-AXL阴性者，但差异未达统计学意义（

＞0.05）。单变量分析显示，男性且p-AXL阳性、Non-GCB型且p-AXL阳性、p-AXL/c-MYC、p-AXL/c-MYC/BCL-2蛋白共表达均是DLBCL患者PFS和OS降低的危险因素（

＜0.05）；但是，多变量分析显示，仅男性且p-AXL阳性、p-AXL/c-MYC蛋白共表达是DLBCL患者PFS和OS降低的显著性危险因素（

＜0.05

；P

＜0.01）。

结论

DLBCL中p-AXL与c-MYC和/或BCL-2的表达、Hans分型、肿瘤化疗缓解率降低和PFS缩短均显著性相关；p-AXL/c-MYC共表达、男性且p-AXL阳性均可作为DLBCL的独立性预后指标。

Abstract

Objective

To investigate the expression and significance of phosphorylated receptor tyrosine kinase（p-AXL）in diffuse large B cell lymphoma (DLBCL)

and the clinical value of its co-expression with BCL-2 and /or

c-MYC

split gene.

Methods

Totally 118 cases of DLBCL were collected in the First Affiliated Hospital of Sun Yat-sen University from 2012 to 2017，and prepared as tissue array. p-AXL

c-MYC and BCL-2 proteins were detected by immunohistochemistry

and c-MYC split gene was detected by FISH staining.

Results

p-AXL protein was stained on tumor cells’ membrane or in the cytoplasm of DLBCL cells. p-AXL was expressed more commonly in Non-GCB type than in GCB type. The expression of p-AXL was significantly correlated with the chemotherapy effect (

0.01)

and the expression of

c-MYC

split gene or BCL-2 protein separately (

0.01). Co-expression of p-AXL and c-MYC

or BCL-2

or both of them was significantly correlated with the Hans typing (

0.01). The PFS of p-AXL positive patients was obviously lower than that of p-AXL negative patients (

0.05). The OS of p-AXL positive patients was also lower than that of the negative patients

but the difference had no statistical significance (

0.05). Univariate analysis showed that p-AXL and male

p-AXL and Non-GCB type

p-AXL and c-MYC co-expression

p-AXL and c-MYC and/or BCL-2 co-expression were the risk factors for PFS and OS in DLBCL patients (

0.05). Multivariate analysis showed that p-AXL positive in male (

0.05) and p-AXL/c-MYC co-expression (

0.01) were independent risk factors for PFS and OS in DLBCL patients.

Conclusions

p-AXL protein is expressed in DLBCL

and its expression is significantly related to the expression of c-MYC and BCL-2. p-AXL expression is associated with lower chemotherapy response rate

shorter progression-free survival and shorter overall survival. p-AXL/c-MYC co-expression or p-AXL positive in male may be an independent prognostic factor for DLBCL patients.

关键词

Keywords

references

Gascoyne RD , Campo E , Jaffe ES , et al . Diffuse large B-cell lymphoma (DLBCL), NOS [M]. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition Lyon : IARC Press , 2017 , 291 - 297 .

Armitage JO , Gascoyne RD , Lunning MA , et al . Non-Hodgkin lymphoma [J]. Lancet , 2017 , 390 （ 10091 ）: 298 - 310 .

Sehn LH , Gascoyne RD . Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity [J]. Blood , 2015 , 125 （ 1 ）: 22 - 32 .

Yang QP , Zhang WY , Yu JB , et al . Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution [J]. Diagn Pathol , 2011 , 6 : 77 .

Antonello S , Paola V , Stefano C , et al . Primary cutaneous DLBCL non-GCB type: challenges of a rare case [J]. Open Med , 2020 , 15 ( 1 ): 119 - 125 .

Schmitz R , Wright GW , HuangDW , et al . Genetics and pathogenesis of diffuse large B-cell lymphoma [J]. N Engl J Med , 2018 , 378 （ 15 ）: 1396 - 1407 .

Swerdlow SH , Campo E ， Pileri SA , et al . The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J]. Blood , 2016 , 127 （ 20 ）: 2375 - 2390 .

Zhu C , Wei Y , Wei X . AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications [J]. Mol Cancer , 2019 , 18 ( 1 ): 153 .

Zhang S , Xu XS , Yang JX , et al . The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review [J]. Onco Targets Ther , 2018 , 11 : 509 - 519 .

Han J , Tian R , Yong B , et al . Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients [J]. Biochem Biophys Res Commun , 2013 , 435 （ 3 ）: 493 - 500 .

Ennishi D , Mottok A , Ben-Neriah S , et al . Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact [J]. Blood , 2017 , 129 （ 20 ）: 2760 - 2770 .

Rosenthal A , Younes A . High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma [J]. Blood Rev , 2017 , 31 （ 2 ）: 37 - 42 .

Wang WG , Jiang XN , Liu ZB , et al . MYC protein-positive diffuse large B-cell lymphoma features an activated B-cell receptor signal pathway [J]. Am J Surg Pathol , 2017 , 41 : 541 - 549 .

Rosenwald A , Bens S , Advani R , et al . Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium [J]. J Clin Oncol , 2019 , 37 ( 35 ): 3359 - 3368 .

Ott G , Rosenwald A , Campo E . Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification [J]. Blood , 2013 , 122 （ 24 ）: 3884 - 3891 .

Tsai WB , Long Y , Park JR , et al . Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents [J]. Oncogene , 2016 , 35 （ 13 ）: 1632 - 1642 .

Li L , Zhang X , Zhang T , et al . Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL [J]. Clin Lymphoma Myeloma Leuk , 2018 , 18 ( 10 ): 381 - 389 .

Peroja P , Pedersen M , Mantere T , et al . Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP [J]. Sci Rep , 2018 , 8 ( 1 ): 14814 .

Tekin N , Omidvar N , Morris TP , et al . Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score [J]. Oncotarget , 2016 , 7 ( 50 ): 83319 - 83329 .

Hu S , Xu-Monette ZY , Tzankov A , et al . MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program [J]. Blood , 2013 , 121 （ 20 ）: 4021 - 4031 .

Teoh CS , Lee SY , Chiang SK , et al . Impact of double expression of C-MYC/BCL2 protein and cell of origin subtypes on the outcome among patients with diffuse large B-cell lymphoma: a single asian center experience [J]. Asian Pac J Cancer Prev , 2018 , 19 （ 5 ）: 1229 - 1236 .

Campo E . MYC in DLBCL: partners matter [J]. Blood , 2015 , 126 （ 22 ）: 2439 - 2440 .

陈万青 , 李贺 , 孙可欣 , 等 . 2014年中国恶性肿瘤发病和死亡分析 [J]. 中华肿瘤杂志 , 2018 , 40 ( 1 ): 5 - 13 .

Chen WQ , Li H , Sun KX , et al . Report of cancer incidence and mortality in china, 2014 [J]. Chin J Oncol , 2018 , 40 ( 1 ): 5 - 13 .

Tanaka K , Tokunaga E , Inoue Y , et al . Impact of expression of vimentin and axl in breast cancer [J]. Clin Breast Cancer , 2016 , 16 （ 6 ）: 520 - 526 .

Wu X , Ma W , Zhou Q , et al . AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases [J]. J Cancer Res Clin Oncol , 2017 , 143 （ 10 ）: 1947 - 1957 .

Sadahiro H , Kang KD , Gibson JT , et al . Activation of the receptor tyrosine kinase axl regulates the immune microenvironment in glioblastoma [J]. Cancer Res , 2018 , 78 （ 11 ）: 3002 - 3013 .

Li Y , Jia L , Ren D , et al . Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma [J]. IUBMB Life , 2014 , 66 （ 7 ）: 507 - 518 .

Tian Y , Zhang Z , Miao L , et al . Anexelekto (AXL) increases resistance to EGFR-TKI and activation of AKT and ERK1/2 in non-small cell lung cancer cells [J]. Oncol Res , 2016 , 24 （ 5 ）: 295 - 303 .

Hong J , Maacha S , Belkhiri A . Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma [J]. Mol Oncol , 2018 , 12 （ 12 ）: 2191 - 2208 .

Muller C , Murawski N , Wiesen MH , et al . The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL [J]. Blood , 2012 , 119 （ 14 ）: 3276 - 3284 .

Held G , Murawski N , Zeynalova S , et al . Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL [J]. Clin Adv Hematol Oncol , 2014 , 12 ( 8 Suppl 16 ): 8 - 9 .

浏览量

883

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

二脂酰甘油酰基转移酶2在神经母细胞瘤中的表达及与MYCN表达相关性的分析

儿童肝肿瘤国际协作组和中国儿童肿瘤组新危险度分层在肝母细胞瘤预后评估中的应用比较

老年起病克罗恩病患者的临床特征

核孔蛋白93在神经母细胞瘤患者中的表达及临床意义